Figure 2

Sankey diagram which represents the detail of systemic therapy. Details of systemic therapy in pre-NDE and post-NDE are represented in upper and lower part of the figure, respectively. Duration of therapy in each treatment line is shown in middle yellow frame. Course of therapy in each treatment line is shown in middle green frame. The number of patients in each treatment line is shown in middle blue frame. NAC, neoadjuvant chemotherapy; AC, adjuvant chemotherapy; MVAC, methotrexate, vinblastine, adriamycin and cisplatin; GC, gemcitabine and cisplatin; GCarbo, gemcitabine and carboplatin; PTX, paclitaxel containing regimen; Pem, pembrolizumab; Ave, avelumab; EV, enfortumab vedotin. *Others: including GN (gemcitabine and nedaplatin), MVAN (methotrexate, vinblastine, Adriamycin and nedaplatin), EP (etoposide and cisplatin), ECarbo (etoposide and carboplatin), MEC (mitoxantrone, etoposide and cytarabine), intra-arterial chemotherapy, Nivolumab (clinical trial) and tegafur-uracil. **p value was analyzed using Mann–Whitney U test, ***p value was analyzed using Fisher’s exact probability test.